Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jordan Perlman"'
Autor:
Kacey Chae, MD, Jordan Perlman, MD, Ryan B. Fransman, MD, Christopher L. Wolfgang, MD, PhD, Ana De Jesus-Acosta, MD, Nestoras Mathioudakis, MD
Publikováno v:
AACE Clinical Case Reports, Vol 7, Iss 6, Pp 379-382 (2021)
Objective: We describe a rare case of profound subcutaneous insulin resistance (SIR) presumed due to a paraneoplastic process caused by pancreatic adenocarcinoma that improved with intravenous insulin and tumor resection. Methods: An 80-year-old man
Externí odkaz:
https://doaj.org/article/6f8d0a8eb44945a6a5ece0113c149824
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e67189 (2013)
Non-Fc-binding Anti CD3 antibody has proven successful in reverting diabetes in the non-obese diabetes mouse model of type 1 diabetes and limited efficacy has been observed in human clinical trials. We hypothesized that addition of rapamycin, an mTOR
Externí odkaz:
https://doaj.org/article/470e357e8eee443d894e89877c3017e0
Autor:
Ana De Jesus-Acosta, Kacey Chae, Nestoras Mathioudakis, Ryan B. Fransman, Jordan Perlman, Christopher L. Wolfgang
Publikováno v:
AACE Clinical Case Reports
AACE Clinical Case Reports, Vol 7, Iss 6, Pp 379-382 (2021)
AACE Clinical Case Reports, Vol 7, Iss 6, Pp 379-382 (2021)
Objective We describe a rare case of profound subcutaneous insulin resistance (SIR) presumed due to a paraneoplastic process caused by pancreatic adenocarcinoma that improved with intravenous insulin and tumor resection. Methods An 80-year-old man wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2f87c1163596b53e78a5dcbbb75dd25
http://europepmc.org/articles/PMC8573285
http://europepmc.org/articles/PMC8573285
Autor:
Jordan Perlman, Jennifer Mammen
Publikováno v:
Journal of the Endocrine Society. 6:A443-A444
Checkpoint inhibitor-induced diabetes mellitus (CIADM) is a rare but morbid complication of cancer immunotherapies. The most common presentation is acute hyperglycemia and severe insulin deficiency. Our experience managing 25 patients in our new Immu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ac952d0cfa2e1665a240167aeb2f78a
https://doi.org/10.1210/jendso/bvac150.923
https://doi.org/10.1210/jendso/bvac150.923
Addition of rapamycin to anti-CD3 antibody improves long-term glycaemia control in diabetic NOD mice
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e67189 (2013)
PLoS ONE
PLoS ONE
Aims/Hypothesis Non-Fc-binding Anti CD3 antibody has proven successful in reverting diabetes in the non-obese diabetes mouse model of type 1 diabetes and limited efficacy has been observed in human clinical trials. We hypothesized that addition of ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abccfa03e9122f1826f2db29a37254e9
http://europepmc.org/articles/PMC3691209?pdf=render
http://europepmc.org/articles/PMC3691209?pdf=render